BG Medicine True Health Declines to Assume BG Medicine Galectin-3 Supply Agreement The supply agreement was originally established between BG and the now defunct Health Diagnostics Laboratory, which was formerly BG's biggest customer. BG Medicine to Delist Stock; Posts 44 Percent Drop in 2015 Revenues The company, which counts fewer than 300 holders of its common stock, said that it was delisting due to the resources required to remain a public company. BG Medicine's Shares Plummet After Firm Withdraws Filing for Expanded Use of Galectin-3 Test BG aimed to use the test to assess risk of fatal cardiovascular events in older adults with no history of cardiovascular, cerebrovascular, or vascular disease. BG Medicine Amends Galectin-3 Test Sales Agreement With Abbott The amendment changes product fees Abbott pays to BG Medicine for galectin-3 test sales in exchange for making two payments totaling $1 million. Nasdaq to Delist BG Medicine’s Stock The company was unable to comply with requirements including having a minimum bid price of at least $1 per share and stockholder equity of at least $2.5 million. Nov 17, 2015 BG Medicine Q3 Revenues Down 52 Percent Sep 15, 2015 Nasdaq to Suspend Trading of BG Medicine's Stock Aug 14, 2015 BG Medicine Q2 Revenues Fall 37 Percent Aug 13, 2015 BG Medicine Offering $2.1M in Stocks, Warrants Jul 9, 2015 BG Medicine Effects One-for-Four Reverse Stock Split May 14, 2015 BG Medicine Q1 Revenues Shrink 41 Percent, Loss Narrows May 13, 2015 BG Medicine Inks Financing Agreements for $2.5M Mar 31, 2015 BG Medicine Q4 Revenues Halved; Firm Files for Additional Galectin-3 Test Indication Mar 16, 2015 BG Medicine Receives Notice of Non-compliance from Nasdaq Feb 2, 2015 BG Medicine Granted Continued Listing on Nasdaq as It Works Towards Meeting Requirements Jan 2, 2015 For Proteomics, 2014 Marked by Interest, Critiques from the Broader Community Premium Dec 1, 2014 Nasdaq Issues Second Warning to BG Medicine on Listing Requirement Nov 13, 2014 BG Medicine Revenues Down 31 Percent in Q3 Oct 20, 2014 BG Medicine Stops Paying Non-Employee Directors Sep 12, 2014 People in the News: Kelly Gardner, Josh Molho, Brock Siegel, Gary Zweiger, Jenny Rooke, Chris Hadsell, Katleen Verleysen, Anastasia Rader Premium Sep 12, 2014 BG Medicine Layoffs Cut Company Headcount in Half; Firm Receives Nasdaq Warning Aug 14, 2014 BG Medicine Posts 20 Percent Drop in Q2 Revenues May 16, 2014 BG Medicine Posts 17 Percent Drop in Q1 Revenues as Galectin-3 Sales Continue to Decline Premium May 14, 2014 BG Medicine Posts 17 Percent Drop in Q1 Revenues Apr 3, 2014 BG Medicine Prices Public Offering, Anticipates $8.9M in Net Proceeds Load More Breaking News In Ongoing False Advertising Suit, Judge Allows Natera Counterclaims Against Guardant Health Centogene Strikes Rare Disease Target Discovery Deal With Insilico Medicine Dilated Cardiomyopathy Gene Mutations Point to Possible Therapeutic Strategy Ginkgo Bioworks Acquires Massachusetts COVID-19 Testing Firm Mainz Biomed Taps DCN Dx to Aid European Study of Enhanced ColoAlert Assay Parse Biosciences Partners With Research Instruments for Southeast Asia Distribution The Scan Transplant Tests Edited Pig Kidneys The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient. UK Changes Some Gene-Edited Crop Rules A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says. Pill Works Against Omicron in Lab Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports. Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.